The Injectables: What, When, and Which One?
- Author:
Kristine Corpus
;
Marie Joan Loy
- Publication Type:Journal Article
- MeSH:
Vascular Endothelial Growth Factor A;
Retinal Pigment Epithelium
- From:
Philippine Journal of Ophthalmology
2015;40(1):52-56
- CountryPhilippines
- Language:English
-
Abstract:
Vascular endothelial growth factor (VEGF)
and inflammation. VEGF-A circulates normally in
the body and is essential in endothelial cell growth.
In the pathological state in the eye, hypoxia increases
VEGF-A, promotes growth of neovascularization
and accelerates the breakdown of blood-retinal barrier
and build-up of fluid in or under the neurosensory
retina and retinal pigment epithelium (RPE). It has 6
isoforms; the predominant isoform (most common
of which) is VEGF 165 and is most linked to
neovascularization in the eye. VEGF-A provided the
rationale for targeted drug development. Anti-VEGF
drugs are anti-angiogenic, anti-inflammatory, antifibrotic, and anti-permeable. The rationale for the
use of steroids to treat macular edema is related to
their ability to reduce capillary permeability, to inhibit
the expression of VEGF gene, and to inhibit the
metabolic pathway of VEGF.
- Full text:PJO 19.pdf
